Vanguard Group Inc. Grows Holdings in Tempus AI, Inc. $TEM

Key Points

• Vanguard increased its stake in Tempus AI by 8.7% in Q4 to 10,258,621 shares — roughly 5.77% ownership valued at about $605.8 million.
• Other institutions including Voloridge and BNP Paribas markedly boosted positions, leaving institutional investors with roughly 24.22% of Tempus AI outstanding.
• Company insiders have been net sellers recently — including CEO Eric Lefkofsky’s 166,250‑share sale under a Rule 10b5‑1 plan — with 563,471 shares sold in the last 90 days (≈$29.8M); insiders still hold about 24.26%.

Vanguard Group Inc. increased its position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 8.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,258,621 shares of the company's stock after acquiring an additional 817,014 shares during the quarter. Vanguard Group Inc. owned about 5.77% of Tempus AI worth $605,772,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TEM. Voloridge Investment Management LLC boosted its stake in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock worth $129,708,000 after purchasing an additional 1,039,176 shares during the period. BNP Paribas Financial Markets boosted its stake in Tempus AI by 312.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock worth $102,869,000 after purchasing an additional 965,730 shares during the period. AQR Capital Management LLC bought a new position in Tempus AI in the 2nd quarter worth approximately $54,020,000. Clear Street Group Inc. bought a new position in Tempus AI in the 3rd quarter worth approximately $57,821,000. Finally, First Trust Advisors LP boosted its stake in Tempus AI by 299.4% in the 3rd quarter. First Trust Advisors LP now owns 590,137 shares of the company's stock worth $47,630,000 after purchasing an additional 442,395 shares during the period. 24.22% of the stock is currently owned by institutional investors.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Named to TIME’s 2026 list and expanded clinical reach via a multi‑year collaboration with Keck/USC — boosts brand credibility, supports commercial adoption of Tempus’ AI precision‑medicine tools and expands addressable clinical volume (coverage cites TIME recognition and the Keck Medicine partnership). TIME recognition article Keck partnership article
• Positive Sentiment: Investor‑day visibility and bullish coverage — upcoming Investor Day (management roadmap) and fresh bull writeups may attract momentum buyers and reduce execution uncertainty if management delivers concrete commercialization milestones. Investor day / bull case coverage
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre‑arranged Rule 10b5‑1 plan — provides liquidity/estate planning context but can be interpreted variably by the market; sale was disclosed in an SEC filing. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation mix — some firms trimmed fair‑value slightly and note the recent rally may be a short‑term bounce; coverage is polarized (buy/hold/sell), so flows depend on upcoming execution/metrics. Analyst narrative article
• Negative Sentiment: Class action litigation over genetic data collection in an acquisition — proposed suits raise legal, compliance and remediation cost risk that can pressure sentiment until resolved. Class action article
• Negative Sentiment: Peer comparisons favor Illumina (ILMN) on valuation and earnings outlook — could divert institutional allocation away from TEM if investors prefer a more established genomics exposure. Peer comparison article

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $55.02 on Monday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The company has a market cap of $9.84 billion, a PE ratio of -39.02 and a beta of 4.00. The business has a 50-day simple moving average of $50.65 and a two-hundred day simple moving average of $63.17. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TEM. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research report on Wednesday, February 25th. HC Wainwright increased their price target on Tempus AI from $89.00 to $95.00 and gave the company a "buy" rating in a report on Monday, March 9th. Jefferies Financial Group initiated coverage on Tempus AI in a research note on Monday, April 13th. They issued an "underperform" rating and a $35.00 target price on the stock. JPMorgan Chase & Co. cut their price target on Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 25th. Finally, TD Cowen upgraded Tempus AI from a "hold" rating to a "buy" rating and set a $65.00 price target on the stock in a research note on Monday, April 13th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $71.36.

Insiders Place Their Bets

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the firm's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the sale, the executive vice president owned 126,918 shares of the company's stock, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ryan M. Bartolucci sold 2,902 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $171,363.10. Following the sale, the chief accounting officer directly owned 41,159 shares of the company's stock, valued at $2,430,438.95. This trade represents a 6.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 563,471 shares of company stock valued at $29,837,342. 24.26% of the stock is currently owned by corporate insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.